How much does Vemurafenib cost per month?

The recommended usage of Vemurafenib/Zobovo(Vemurafenib) in the treatment of diseases such as melanoma is 960mg orally every 12 hours, that is, the total daily dose is 1920mg. Based on the specification of 240mg/tablet, patients need to take 8 tablets per day, which is about 240 tablets per month (about 30 days). If calculated based on the domestic original drug (240 mg × 56 tablets/box), approximately 4.3 boxes of drugs are needed per month. Based on the current market price of about 5,000 yuan per box, the monthly drug cost is about 21,000 yuan. However, after inclusion in medical insurance reimbursement, patients' actual out-of-pocket expenses usually drop significantly, and the specific amount depends on local policies.

In the European and American markets, the original price of vemurafenib is generally higher than that in Asian countries. The monthly treatment cost in the United States was once as high as tens of thousands of dollars. The prices of the Turkish European version and the Indian imitation version are more cost-effective. At the same dose, if you use the European version of the drug, it will cost about 13,000 yuan a month; if you use the Laos generic version, it may be as low as about 8,000 yuan (the price changes with exchange rates and channels).

It is worth noting that vemurafenib is a long-term oral targeted drug, and patients need to continue taking it as directed by their doctor to maintain the inhibitory effect of the BRAF signaling pathway. Interruption or automatic dose reduction may lead to tumor cell reactivation, thus affecting efficacy. Doctors usually adjust the dose based on the patient's tolerance and adverse reactions, and regularly test liver function and skin reactions.

With medical insurance coverage, the financial burden of domestic patients has been significantly reduced. For example, some provinces and cities have included Vemurafenib in the "direct payment for special drugs" project, with the reimbursement rate reaching 70%-80%. This means that many patients’ actual monthly costs may be significantly lower than in the early out-of-pocket period.

In summary, the monthly cost of vemurafenib depends on the drug version and health insurance policy. As competition from international generic drugs intensifies, the price of vemurafenib is expected to continue to fall in the future, providing a more economical long-term treatment option for patients with BRAF mutant tumors.

Reference: https://www.drugs.com/mtm/vemurafenib.html